Combination of C-X-C motif chemokine 9 and C-X-C motif chemokine 10 antibodies with @entity20083 prolongs the survival of cardiac retransplantation allografts in a XXXX model.

@entity12426 @entity2047 @entity19 @entity641 @entity20083 @entity1618 @entity299 @entity15369
UNASSIGNED: The upregulation of chemokine genes and the subsequent T-lymphocyte recruitment to the graft are early events in the development of @entity299 or @entity299 . In the present study, a combined immunosuppressive regimen of C-X-C motif chemokine 9 ( @entity12426 ) antibody (Ab), @entity15369 Ab and @entity20083 was used in order to reduce the infiltration of memory T lymphocytes and prolong graft survival in a retransplantation @entity19 model. BALB/c donor hearts were transplanted heterotopically into C57BL/6 @entity19 at day 28 after skin transplantation. The @entity19 were divided into four groups: i) Control (normal saline), ii) @entity12426 Ab and @entity15369 Ab [150  g; once daily (qd); intraperitoneal (ip)], iii) @entity20083 (0.2 mg/day; qd; ip) and iv) combined (2 mg/kg/day; qd; ip). Measurements of the median survival time of the cardiac grafts, histological examination, reverse transcription-quantitative polymerase chain reaction analysis, enzyme-linked immunosorbent assay and a mixed lymphocyte reaction were performed. The median graft survival time of the combined group was prolonged (9.3 days) compared with that of the control group (3.5 days) (P<0.001). Histological examination revealed that the combined treatment group graft rejection pathological score was 0.50, while the control group score was 3.62 (P<0.001). In addition, the gene expression level of @entity2047 was significantly lower and the levels of @entity1618 and @entity641 ( @entity641 ) were significantly higher in the combined group compared with those in the control group (P<0.001). Furthermore, the serum concentration levels of @entity2047 and interferon-y (IFN-y) were significantly lower (P<0.001) and the concentration of @entity1618 was significantly higher (P<0.05) in the combined group compared with those in the control group. In the mixed lymphocyte reaction, T-cell proliferation was found to be significantly lower in the combined treatment group than that in the control group (P<0.001). In conclusion, treatment with @entity12426 Ab and @entity15369 Ab or @entity20083 reduced the graft infiltration of inflammatory cells, inhibited T-cell proliferation and prolonged graft survival. The combined treatment regimen of @entity12426 Ab, @entity15369 Ab and @entity20083 was found to significantly reduce the infiltration of inflammatory cells in the graft and prolong graft survival.
